Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID ...

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an ...

Changing the paradigm on hypermobile Ehlers-Danlos Syndrome: Connective tissues don't tell the whole story

Recent research from the Medical University of South Carolina laboratory of Russell Norris, Ph.D., challenges the notion that ...

A Constructive Critique of New York’s 'Raise the Age' Legislation

Retired Judge Michael Corriero was instrumental in creating Manhattan's Youth Part in the Supreme Court of New York County, a ...